Argenx: Up To $1.15 Billion Acquisition Of Unnatural Products To Expand Peptide Drug Discovery Platform
Argenx (ARGX) agreed to acquire Unnatural Products (UNP) for up to $1.15B, including $550M upfront. The deal expands Argenx's drug discovery platform to include macrocyclic peptides, potentially enabling oral and long-acting treatments. UNP's tech will complement Argenx's antibody engineering expertise. The transaction is expected to close by late 2026, subject to conditions.
How this was made

The 30-second read
Why it matters
The deal provides argenx with a new discovery engine, potentially diversifying its product portfolio and creating oral/long‑acting candidates.
Market read
First‑report M&A of over $1 billion in biotech, likely to move argenx's stock and influence sector dynamics.
What to watch
Regulatory milestones tied to the $595 million contingent payments could affect future cash outflows.
Background
argenx, a NASDAQ‑listed immunology biotech, is expanding its pipeline by acquiring macrocyclic peptide developer Unnatural Products.
Market effects
strengthens the biotech sector's focus on peptide therapeutics and may spur similar deals.
European‑listed biotech may see heightened M&A activity.
adds to the broader trend of biotech firms expanding beyond antibodies.
Counterpoint
The premium paid may be excessive if peptide platform integration faces delays.
Key entities
- companyargenx
US‑listed biotech acquiring UNP.
- companyUnnatural Products
Private peptide drug discovery firm.


